Tags

Type your tag names separated by a space and hit enter

Determination of the angiotensin-converting enzyme inhibitor quinapril and its metabolite quinaprilat in pharmaceuticals and urine by capillary zone electrophoresis and solid-phase extraction.
Electrophoresis. 2002 Jan; 23(1):102-9.E

Abstract

Quinapril is an antihypertensive drug commonly used in the treatment of hypertension and congestive heart failure. In this work, a capillary zone electrophoresis system is optimized for the analysis of quinapril and its active metabolite quinaprilat in urine, as well as for the determination of the drug and its combination with hydrochlorothiazide in pharmaceuticals. The separation takes place in a fused-silica capillary. The running electrolyte consists of a 60 mM borate buffer solution, pH 9.5. The analysis of urine samples requires a previous extraction step using C8 solid-phase cartridges. Under the optimum experimental conditions, the separation of the two analytes and the internal standard takes less than 5 min. The detection limits obtained (75 and 95 ng/mL for quinapril and quinaprilat, respectively) allow the application of the electrophoretic method to the determination of the drug and its metabolite in urine samples obtained from four patients treated with quinapril.

Authors+Show Affiliations

Departamento de Química Analítica, Facultad de Ciencias, Universidad del País, Vasco UPV/EHU, Bilbao, Spain.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Validation Study

Language

eng

PubMed ID

11824610

Citation

Prieto, José Angel, et al. "Determination of the Angiotensin-converting Enzyme Inhibitor Quinapril and Its Metabolite Quinaprilat in Pharmaceuticals and Urine By Capillary Zone Electrophoresis and Solid-phase Extraction." Electrophoresis, vol. 23, no. 1, 2002, pp. 102-9.
Prieto JA, Alonso RM, Jiménez RM. Determination of the angiotensin-converting enzyme inhibitor quinapril and its metabolite quinaprilat in pharmaceuticals and urine by capillary zone electrophoresis and solid-phase extraction. Electrophoresis. 2002;23(1):102-9.
Prieto, J. A., Alonso, R. M., & Jiménez, R. M. (2002). Determination of the angiotensin-converting enzyme inhibitor quinapril and its metabolite quinaprilat in pharmaceuticals and urine by capillary zone electrophoresis and solid-phase extraction. Electrophoresis, 23(1), 102-9.
Prieto JA, Alonso RM, Jiménez RM. Determination of the Angiotensin-converting Enzyme Inhibitor Quinapril and Its Metabolite Quinaprilat in Pharmaceuticals and Urine By Capillary Zone Electrophoresis and Solid-phase Extraction. Electrophoresis. 2002;23(1):102-9. PubMed PMID: 11824610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Determination of the angiotensin-converting enzyme inhibitor quinapril and its metabolite quinaprilat in pharmaceuticals and urine by capillary zone electrophoresis and solid-phase extraction. AU - Prieto,José Angel, AU - Alonso,Rosa María, AU - Jiménez,Rosa María, PY - 2002/2/5/pubmed PY - 2003/8/26/medline PY - 2002/2/5/entrez SP - 102 EP - 9 JF - Electrophoresis JO - Electrophoresis VL - 23 IS - 1 N2 - Quinapril is an antihypertensive drug commonly used in the treatment of hypertension and congestive heart failure. In this work, a capillary zone electrophoresis system is optimized for the analysis of quinapril and its active metabolite quinaprilat in urine, as well as for the determination of the drug and its combination with hydrochlorothiazide in pharmaceuticals. The separation takes place in a fused-silica capillary. The running electrolyte consists of a 60 mM borate buffer solution, pH 9.5. The analysis of urine samples requires a previous extraction step using C8 solid-phase cartridges. Under the optimum experimental conditions, the separation of the two analytes and the internal standard takes less than 5 min. The detection limits obtained (75 and 95 ng/mL for quinapril and quinaprilat, respectively) allow the application of the electrophoretic method to the determination of the drug and its metabolite in urine samples obtained from four patients treated with quinapril. SN - 0173-0835 UR - https://www.unboundmedicine.com/medline/citation/11824610/Determination_of_the_angiotensin_converting_enzyme_inhibitor_quinapril_and_its_metabolite_quinaprilat_in_pharmaceuticals_and_urine_by_capillary_zone_electrophoresis_and_solid_phase_extraction_ L2 - https://doi.org/10.1002/1522-2683(200201)23:1<102::AID-ELPS102>3.0.CO;2-C DB - PRIME DP - Unbound Medicine ER -